Stanford Neuromodulation Therapy (SNT) for the Treatment-Resistant Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

130 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-22

Study Completion Date

2024-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a multicenter, randomized, double-blind, and sham-controlled trial using the identical protocol as the SNT to replicate the antidepressant efficacy of SNT for TRD. Patients will be recruited and randomly assigned (1:1 ratio) to receive active or sham groups from 5 hospitals in China. The interventions will last for 5 days and both groups will be followed up for 8 weeks on the same time schedules. During the intervention and at least the first 4 weeks of post-treatment, participants will keep a stable antidepressant regimen. The individualized SNT target in the left dorsolateral prefrontal cortex (DLPFC) will be generated from 30 minutes of resting-state functional MRI collected at baseline.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment of Post-Traumatic Brain Injury (TBI) Depression

NCT00233103

Depression

COMPLETED PHASE2

The Research of Ammoxetine Hydrochloride Enteric-coated Tablets in Subjects With Depression

NCT06827431

Major Depressive Disorder (MDD)

NOT_YET_RECRUITING PHASE3

Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

NCT00232167

Insomnia Depression

TERMINATED PHASE3

Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.

NCT03435744

Treatment Resistant Depression Major Depressive Disorder

COMPLETED PHASE3

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT04533529

Depressive Disorder, Major

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Repetitive Transcranial Magnetic Training (rTMS) is a non-invasive neuromodulation that has been approved by the Food and Drug Administration (FDA) for treating patients with treatment-resistant depression(TRD). In 2022, the US FDA approved a high-dose intervention called Stanford Neuromodulation Therapy (SNT) to achieve rapid relief of patient symptoms in TRD. This therapy involves 10 1800 pulse Intermittent Theta Burst Stimulation (iTBS) interventions per day for consecutive 5 days on the dorsolateral prefrontal cortex (DLPFC), with 50 minutes inter-session intervals. At the end of the SNT intervention, the response rate reached 71.4% (13.3% in the sham group); At the 4th week follow-up after treatment, the response rate was 69.2% (7.1% in the sham group). This therapy has the advantage of quickly taking effect in the treatment of patients with TRD in a short period. However, there are also some limitations with this therapy, such as the need to undergo 10 high-dose interventions with 1800 pulses per day, which takes about 9 hours and may reduce patient compliance with the treatment. In addition, this study is a single-center small sample trial (14 cases with active and 15 cases with sham stimulation). The SNT therapy brings confidence to TRD patients, its efficacy and safety need to be verified in multicenter, randomized, double-blind, placebo-parallel controlled clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Treatment Resistant Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active iTBS-DLPFC

The active group will receive active iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.

Group Type EXPERIMENTAL

Active iTBS-DLPFC

Intervention Type DEVICE

Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.

Sham iTBS-DLPFC

The sham group will receive sham iTBS. Treat 10 times a day with 1800 pulses per day for consecutive 5 days, with 50 minutes inter-session intervals.

Group Type SHAM_COMPARATOR

Sham iTBS-DLPFC

Intervention Type DEVICE

The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Active iTBS-DLPFC

Participants will receive 10 sessions per day of 1800 pulses per session, lasting for 5 days.

Intervention Type DEVICE

Sham iTBS-DLPFC

The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meet the diagnostic criteria of DSM-5(Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) for depression disorder without psychotic symptoms, and currently experiencing a recurrence episode;
* Hamilton Depression Scale (HAMD-17) scores for 17 items ≥ 20 points, and the Montgomery Asberg Depression Rating Scale (MADRS) score is ≥ 20 points;
* hospitalized/outpatient patients aged ≥ 22 and ≤ 65 years old, male or female;
* The Maudsley Staging Method (MSM) assesses patients as at least moderate refractory (MSM score ≥ 7 points);
* Stable use of antidepressants for 4 weeks before randomization, with the type of antidepressant used being selective serotonin reuptake Selective serotonin reuptake inhibitors (SSRIs) or/and serotonin and norepinephrine reuptake Serotonin-norepinephrine reuptake inhibitors (SNRIs), the therapeutic dose is within the dosage range as the drug manual recommended;
* Understand the trial and sign the informed consent form.

Exclusion Criteria

* Meets DSM-5 diagnostic criteria for other mental disorders, including schizophrenia spectrum disorders, bipolar and related disorders, and psychiatric disorders Developmental disorders, neurocognitive disorders, or depression caused by substances and/or drugs, or other medical problems;
* Individuals with pacemakers, cochlear implants, or other metal objects, as well as any electronic devices implanted in the body, and those with claustrophobia Contraindications for magnetic resonance imaging scans such as fear, and contraindications for rTMS treatment;
* History of epilepsy (presence of at least 2 uninduced seizures more than 24 hours apart, or diagnosis of the epileptic syndrome, or seizures within the past 12 months); Or currently received medications or other treatments that will lower the seizure threshold Syndromes, or seizures within the past 12 months;
* Received TMS treatment before participating in the trial;
* Individuals who have received ECT or phototherapy within three months;
* No response to ECT treatment (\>8 times);
* Previously received antidepressant treatment with implanted devices (such as DBS, VNS);
* Concomitant organic brain diseases (such as ischemic stroke, cerebral hemorrhage, brain tumors, etc.) and a history of severe brain injury;
* Complicated with serious heart, liver, kidney diseases, diabetes, and other serious physical diseases, which cause abnormal symptoms and signs of brain nerves, Or physical exhaustion;
* Women of childbearing age who are currently pregnant, breastfeeding, or planning or may become pregnant during the trial period;
* Substance abuse or dependence (including alcohol, drugs, and other psychoactive substances) in the past year;
* First-degree relatives suffer from bipolar disorder;
* High risk of suicide;
* Difficulty in communication to understand or follow instructions, and unable to cooperate with treatment and evaluation;
* Current in clinical trials of other drugs or physical therapies (DBS, ECT, rTMS);
* The researchers believe it is not suitable to participate.

Minimum Eligible Age

22 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No